Itziar Erkizia Jauregi
Tècnic/a sènior de laboratori
Grup de recerca
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.
Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression.
Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.